Eli Lilly
Novo’s Weight-Loss Drug Shows Better Lean Mass Preservation Than Lilly’s
Novo’s weight-loss drug has been found to preserve lean body mass better than Lilly’s, marking a significant advancement in obesity treatment options.
Eli Lilly’s Foundayo Shows Promising Results for Type 2 Diabetes Management
Eli Lilly’s Foundayo shows promising results in managing Type 2 diabetes, emphasizing safety and efficacy in cardiometabolic health.
Eli Lilly’s Market Share Declines as Novo Nordisk Maintains Position
Eli Lilly’s market share is declining in India due to generic weight-loss drugs, while Novo Nordisk maintains a stable position amidst competition.
Eli Lilly Partners with InSilico for $2.75 Billion AI Drug Discovery Initiative
Eli Lilly has entered a $2.75 billion partnership with InSilico Medicine to enhance AI-driven drug discovery, promising rapid advancements in pharmaceuticals.
Eli Lilly Partners with InSilico for Revolutionary AI Drug Discovery
Eli Lilly has signed a $2.75 billion partnership with InSilico Medicine to enhance drug discovery through AI technology, marking a significant industry milestone.
Eli Lilly Partners with InSilico for Revolutionary AI Drug Discovery
Eli Lilly has partnered with InSilico Medicine for a $2.75 billion AI drug discovery deal, promising to innovate pharmaceutical development.